Recently, the new production base of JSBY Life Technology Corporation was officially put into production. The production base mainly produces the first "artificial blood vessel[Vascular Prosthesis/Vascular Graft]" which independently developed by JSBY.
This means that the bottleneck technology of "artificial blood vessel", which has plagued China for a long time, has been broken. After the product is officially launched, it will break the market monopoly of foreign giants for nearly 60 years.
On November 17, 2022, the artificial blood vessel independently developed and produced by JSBY was approved for listing by the National Drug Administration (NMPA) of China. This is the first domestic artificial blood vessel approved for listing by the National Drug Administration. Its performance exceeds the gold standard of imported products. After listing, it will fill the technical gap in the field of artificial blood vessels in China and break the market monopoly of overseas giants for nearly 60 years.